3.84
price up icon1.05%   0.04
after-market アフターアワーズ: 3.98 0.14 +3.65%
loading

Revance Therapeutics Inc (RVNC) 最新ニュース

pulisher
Nov 20, 2024

Revance Therapeutics sinks amid `going concern' disclosure - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Alpine Associates Management Inc. Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Revance and Crown extend merger offer date to November 26 - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Revance and Crown extend merger offer date to November 26 By Investing.com - Investing.com Nigeria

Nov 20, 2024
pulisher
Nov 19, 2024

Revance Therapeutics gains as Crown Labs further extends tender offer - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

LMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat

Nov 18, 2024
pulisher
Nov 14, 2024

Neurotoxin Market Overall Study Report 2024-2032 | Revance - openPR

Nov 14, 2024
pulisher
Nov 12, 2024

Revance, Crown Labs Again Extend Tender Offer Start Deadline - MarketWatch

Nov 12, 2024
pulisher
Nov 12, 2024

Revance Therapeutics jumps after Crown Laboratories tender offer extended again - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts - MarketBeat

Nov 12, 2024
pulisher
Nov 10, 2024

StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders - GlobeNewswire Inc.

Nov 09, 2024
pulisher
Nov 08, 2024

Where are the Opportunities in (RVNC) - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

Revance Therapeutics (NASDAQ:RVNC) Given Hold Rating at Needham & Company LLC - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Revance Therapeutics' (RVNC) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

Revance Therapeutics Reports Q3 Growth Amid Merger Plans - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Revance Therapeutics Q3 2024 Earnings: EPS of -$0.37 Beats Estimate, Revenue of $59.9M Misses Expectations - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Revance Q3 Revenue Up 11% to $59.9M Amid Crown Merger Deal; China Approves DAXXIFY | RVNC Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Top 10 startups in Dermatology in Bay Area, United States in Nov, 2024 - Tracxn

Nov 07, 2024
pulisher
Oct 30, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing

Oct 30, 2024
pulisher
Oct 29, 2024

Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Crown Settles Customer Dispute To Close $924M Revance Buy - Law360

Oct 28, 2024
pulisher
Oct 28, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com

Oct 28, 2024
pulisher
Oct 27, 2024

Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN

Oct 27, 2024
pulisher
Oct 25, 2024

Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat

Oct 25, 2024
pulisher
Oct 19, 2024

Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India

Oct 19, 2024
pulisher
Oct 18, 2024

Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 18, 2024

Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch

Oct 18, 2024
pulisher
Oct 18, 2024

Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire

Oct 17, 2024
pulisher
Oct 17, 2024

The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire

Oct 17, 2024
pulisher
Oct 17, 2024

(RVNC) Trading Signals - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 17, 2024

StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com

Oct 15, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
大文字化:     |  ボリューム (24 時間):